Intelligence Report · ~12 min read
Alnylam Pharmaceuticals Intelligence Report
Generated from 1 signals · 2 evidence sources
Type
Company Intelligence ReportGenerated
Jun 21, 2026
Confidence
Moderate Confidence · 72%
Evidence
6 items
Sources
5
Executive Summary
Synthesized assessment from linked signals, findings, and evidence relationships.
Alnylam Pharmaceuticals maintains an active intelligence profile across Oncology, Hepatocellular Carcinoma. 1 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with low portfolio impact. Evidence coverage stands at 72% across 2 tracked sources. Highest-priority development: October - December 2024 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS). Regulatory precedent. Why this matters: sets a safety guidance precedent in the same sub-indication (liver cancer) as Alnylam Pharmaceuticals.
Key Developments
Material intelligence events ranked by strategic relevance.
- regulatory
October - December 2024 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
Regulatory precedent may inform portfolio positioning
View detail - regulatory
S6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived Pharmaceuticals
Regulatory precedent may inform portfolio positioning
View detail - regulatory
New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
Regulatory precedent may inform portfolio positioning
View detail - regulatory
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
Regulatory precedent may inform portfolio positioning
View detail - regulatory
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Regulatory precedent may inform portfolio positioning
View detail
Strategic Implications
Portfolio and competitive decisions informed by this intelligence profile.
Opportunity score 16 with buyer quality 6 (Emerging). Competitive pressure: Low. Portfolio impact: Low.
Supporting Evidence
Evidence-backed items with source attribution and confidence disclosure.
October - December 2024 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
Moderate Confidence · 72%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceS6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived Pharmaceuticals
Moderate Confidence · 72%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceNew Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
Moderate Confidence · 72%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceJanus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
Moderate Confidence · 72%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceFDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Moderate Confidence · 72%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Signals
- Alnylam's ALN-BCAT Study in Hepatocellular Carcinoma Evaluates Safety and Efficacy
Oncology · Hepatocellular Carcinoma